TITLE:
Triple Effect of Doxorubicin, 5-Fluorouracil, Propranolol on Cell Survival on MCF-7 Breast Cancer Cell Line
AUTHORS:
Onur Eroglu, Hacer Kaya, Esin Guvenir Celik, Merve Celen, Elif Korkut, Nagihan Nizam
KEYWORDS:
MCF-7, Breast Cancer, Combine Treatment, Doxorubicin, 5-Fluorouracil, Propranolol
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.7 No.2,
February
14,
2019
ABSTRACT: Purpose: Investigating the
triple effect of doxorubicin, 5-fluorouracil, propranolol on MCF-7 (ER+, WTp53)
breast cancer cell line with MTT test and survival analysis. Materials/Methods: In order to determine effective dosages of a combination of doxorubicin,
5-fluorouracil, propranolol on the MCF-7 cell line by using MTT and survival
analysis technique. Result: IC50 values acquired by MTT tests
are 0.01 mg/ml for doxorubicin, 6 mg/ml for 5-fluorouracil, 30 mg/ml for
propranolol and 0.2/1/30 mg/ml (with previous respect) if all three agents are
combined. It is found that the use of doxorubicin, 5-fluorouracil, and
propranolol in combination is much effective than their single application. Discussion: Moderate concentrations of doxorubicin, 5-fluorouracil, and propranolol, if they
are applied individually, showed high toxicity. When we used these drugs in
combination; toxic effects lessened with respect to monotherapy. In the MCF-7
cell line, doxorubicin (IC50: 0.01 μM) increases cell death rates
significantly and propranolol (IC50: 3 μM) has minimum effects in
monotherapy in contrast to others. Propranolol is only superior to itself in
combination therapy (IC50: 4 μM). However 5-fluorouracil
(IC50: 30 μM) showed antagonistic effects with respect to other
drugs. Additionally, having applied the three drugs in combination on the MCF-7
cell line for the first time in literature, it is highly possible to assess the
application of doxorubicin, 5-fluorouracil and propranolol combination as a
novel therapy option.